Ozempic maker sues US rival over ad campaign

A Danish pharmaceutical giant, Novo Nordisk, has filed a lawsuit against its U.S.-based competitor, Eli Lilly, accusing the American firm of running deceptive advertising campaigns. The legal action was announced on Tuesday and centers around Eli Lilly’s marketing of its weight-loss drugs Mounjaro and Zepbound, which Novo Nordisk claims uses outdated and selectively presented data to mislead consumers. The lawsuit was filed in a U.S. district court in New Jersey and alleges violations of fair competition laws and federal false advertising statutes. According to Novo Nordisk, Eli Lilly’s advertisements compare higher doses of Novo Nordisk’s popular GLP-1 agonists Wegovy and Ozempic with lower doses of Eli Lilly’s products. This comparison, the Danish company argues, creates a misleading impression of overall product superiority. The ads, which were aired during major global sporting events and on social media platforms such as TikTok and Facebook, are said to obscure crucial clinical context, according to the lawsuit. John F. Kuckelman, general counsel at Novo Nordisk, stated that patients should receive accurate information based on the latest scientific research to help them make informed healthcare choices. He emphasized the importance of transparency in advertising, particularly as newer and more effective treatments continue to emerge in the market. The dispute arises amid a surge in demand for weight-loss medications, with both Novo Nordisk and Eli Lilly benefiting significantly from the growing popularity of their respective drugs. These medications, known as GLP-1 agonists, mimic the body’s natural GLP-1 hormone, which regulates appetite and is released after eating. Both companies have developed separate synthetic versions of these hormones, which are used to treat type 2 diabetes and aid in weight management. Eli Lilly’s advertising strategy appears to focus on highlighting specific study outcomes that favor its products under certain conditions. Novo Nordisk contends that these studies are outdated and cherry-picked to create a false narrative of competitive advantage. The company says Eli Lilly’s approach undermines consumer trust and distorts the marketplace by presenting incomplete or misleading information. The legal battle comes at a time when the weight-loss drug market is experiencing rapid growth, driven largely by the success of GLP-1 agonists. Both Novo Nordisk and Eli Lilly have seen substantial revenue increases due to the rising demand for these medications, particularly in regions such as the United Kingdom, where their use has surged. Experts suggest that the outcome of this case could set a precedent for how pharmaceutical companies advertise their products, especially in a highly competitive market. The lawsuit highlights concerns about the accuracy and ethical standards of drug promotion, particularly when it involves complex medical information that can influence patient decisions. The case will likely involve detailed scrutiny of the studies cited in Eli Lilly’s advertisements, as well as an examination of whether the company adequately disclosed limitations or contextual factors that could affect the interpretation of its findings. Legal experts anticipate that the trial could last several months, with potential implications for future advertising practices within the industry. As the litigation progresses, both companies are expected to present extensive evidence regarding the validity of their claims and the integrity of their marketing strategies. The resolution of this case could impact not only the current market dynamics but also the regulatory landscape governing pharmaceutical advertising in the United States.